Generation of HPV-specific T-cells
AssigneeBaylor College of Medicine
InventorsCarlos A. Ramos, Cliona M. Rooney, Neeharika Narala
Life of this patent
Estimating the term…
Abstract
Embodiments of the disclosure concern methods and compositions for immunotherapy for human papillomavirus infection and diseases associated therewith. In specific embodiments, methods concern production of immune cells that target one or more antigens of HPV16 and/or HPV18, including methods with stimulation steps that employ IL-7 and IL-15, but not IL-6 and/or IL-12. Other specific embodiments utilize stimulations in the presence of certain cells, such as costimulatory cells and certain antigen presenting cells.
Claims17
A method of producing a pharmaceutical composition comprising T-cells specific for human papillomavirus (HPV), the method comprising:
- (a) stimulating peripheral blood T-cells with antigen presenting cells in the presence of interleukin (IL)-7 and IL-15, and in the presence of IL-6 and/or IL-12, wherein the peripheral blood T-cells are not tumor-infiltrating lymphocytes, and further wherein the antigen presenting cells were previously exposed to one or more peptides, wherein the peptides comprise sequence that corresponds to at least part of the sequence of one or more proteins of HPV;
- (b) stimulating the T-cells obtained at step (a) with antigen presenting cells in the presence of IL-7 and IL-15 and in the absence of IL-6 and IL-12, wherein the antigen presenting cells were previously exposed to one or more peptides, wherein the peptides comprise sequence that corresponds to at least part of the sequence of one or more proteins of, thereby expanding HPV-specific T cells;
- and
- (c) formulating the population of cells obtained at step (b) to a pharmaceutical composition suitable for administration to a human subject.
A method of producing a pharmaceutical composition comprising T-cells specific for human papillomavirus (HPV) the method comprising:
- (a) stimulating peripheral blood T-cells specific for HPV or for an HPV antigen with antigen presenting cells in the presence of interleukin (IL)-7 and IL-15, and in the presence of IL-6 and/or IL-12, wherein the peripheral blood T-cells are not tumor-infiltrating lymphocytes, and further wherein the antigen presenting cells were previously exposed to one or more peptides, wherein the peptides comprise sequence that corresponds to at least part of the sequence of one or more proteins of HPV;
- (b) stimulating the T-cells obtained at step (a) with antigen presenting cells in the presence of IL-7 and IL-15, in the absence of IL-6 and IL-12, and in the presence of co-stimulatory cells, wherein the antigen presenting cells were previously exposed to one or more peptides, wherein the peptides comprise sequence that corresponds to at least part of the sequence of one or more proteins of HPV;
- and
- (c) formulating the population of cells obtained at step (b) to a pharmaceutical composition suitable for administration to a human subject.
Dependencies are inferred from the claim text.